Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push
A pharmaceutical company called Viatris is buying another company called Pacira BioSciences for $1.65 billion. Pacira specializes in non-opioid pain treatments. The purchase price is $36.50 per share, which is about 45% higher than Pacira's previous value. The deal is expected to be completed by the end of 2026.
3 across the spectrum. Choose a side on the bar to jump to it.
National story. 3 articles from 3 sources. Updated 7d ago.
How each side is putting it
Left
1 viewpointViatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push
Center
0 viewpointsNo Center coverage yet.
A blind spot on this side of the story.
Right
2 viewpointsPacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly